Elicit —Analyze research papers at superhuman speed

We envision a future where the power of good reasoning is amplified through advanced machine learning, enabling complex and nuanced thinking across diverse scientific fields. Our mission is to transform how knowledge is discovered, synthesized, and applied by harnessing AI to scale thoughtful, evidence-based decision-making beyond traditional automation.

At Elicit, we are building a platform that revolutionizes scientific research workflows by integrating cutting-edge language models with vast academic databases. Our technology empowers researchers to uncover deeper insights with semantic search, automate intricate data extraction, and generate comprehensive, transparent research reports that support systematic inquiry and reflection.

We exist to drive meaningful progress in human understanding and innovation by creating AI tools that enhance reasoning and careful thought, fostering a world where evidence guides smarter choices across academia, industry, and society at large.

We've been tracking Elicit since it spun out of the nonprofit research lab Ought, and honestly, we're impressed by how they've tackled one of academia's biggest pain points. If you've ever tried to sift through hundreds of research papers for a literature review, you know the struggle is real.

What Makes Elicit Different

While most research tools still rely on clunky keyword searches, Elicit uses semantic search that actually understands what you're looking for. We tested it ourselves, and it's surprisingly good at finding relevant papers even when you don't nail the exact terminology. The platform searches through 125+ million academic papers and clinical trials, which is pretty comprehensive coverage.

What really caught our attention is how it automates the tedious parts of research. Instead of manually extracting data from each paper, Elicit can pull out key details like study populations, interventions, and outcomes into organized tables. It's like having a research assistant who never gets tired.

The Numbers Tell a Story

With over 400,000 monthly users including researchers from Harvard, MIT, and companies like Genentech, Elicit has clearly struck a nerve. Their recent $22 million Series A at a $100 million valuation shows investors believe in the vision too.

We're particularly intrigued by their expansion beyond academia into pharmaceutical companies and consulting firms. It suggests the platform's utility extends far beyond traditional research settings.

Where It Shines (And Where It Might Struggle)

Elicit excels at systematic reviews and evidence synthesis – tasks that typically take weeks but can now be done in hours. The AI-generated research reports and customizable data extraction features are genuinely useful for anyone doing evidence-based work.

However, we'd caution that it's still an AI tool, which means you'll want to verify critical findings manually. The platform seems most valuable for researchers who understand its limitations and use it to accelerate rather than replace human judgment.

For academic researchers, systematic reviewers, and anyone in biomedicine or pharma doing literature-heavy work, Elicit feels like a legitimate game-changer. It's one of those rare AI tools that actually solves a real problem rather than creating a solution in search of one.